

HR 5281

Drug Price Transparency in Medicaid Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 3, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 4, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5281>

Sponsor

Name: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Dec 3, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 4, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 3	Related bill	Sep 8, 2020: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
116 S 4199	Related bill	Jul 2, 2020: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 S 2543	Related bill	Sep 25, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.

Summary (as of Dec 3, 2019)

Drug Price Transparency in Medicaid Act of 2019

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.

Actions Timeline

- **Dec 4, 2019:** Referred to the Subcommittee on Health.
- **Dec 3, 2019:** Introduced in House
- **Dec 3, 2019:** Referred to the House Committee on Energy and Commerce.